利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.018 秒)

    Method of reducing side effects associated with administration of oxygen-carrying proteins
    19.
    发明授权
    Method of reducing side effects associated with administration of oxygen-carrying proteins 失效
    降低与携带携带蛋白质的给药相关的副作用的方法

    公开(公告)号：US5900402A

    公开(公告)日：1999-05-04

    申请号：US865035

    申请日：1997-05-29

    申请人： Robert G. L. Shorr

    发明人： Robert G. L. Shorr

    IPC分类号： A61K38/42 ,  A61K47/48 ,  A01N37/18 ,  A61K38/16 ,  C07K14/00 ,  C07K16/00

    CPC分类号： A61K47/48215 ,  A61K38/42

    摘要： A method of reducing side-effects associated with administering oxygen-carrying proteins to mammals is disclosed. The method includes:a) reacting an oxygen-carrying protein with a substantially non-antigenic polymer to form a oxygen-carrying protein-substantially non-antigenic polymer conjugate; andb) administering the oxygen-carrying protein-substantially non-antigenic polymer conjugate to a mammal in need of the oxygen-carrying protein. Preferred oxygen-carrying proteins include recombinantly prepared hemoglobins and preferred non-antigenic polymers include polyethylene glycol.

    摘要翻译： 公开了一种减少与哺乳动物施用携氧蛋白相关的副作用的方法。 该方法包括：a）使携氧蛋白与基本上非抗原性聚合物反应以形成携氧蛋白基本上非抗原性的聚合物缀合物; 和b）向需要携氧蛋白的哺乳动物施用载氧蛋白 - 基本上非抗原性的聚合物缀合物。 优选的携氧蛋白包括重组制备的血红蛋白，优选的非抗原性聚合物包括聚乙二醇。

    Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
    20.
    发明授权
    Method of treating CD4+ T cell lymphopenia in immuno-compromised patients 失效
    免疫缺陷患者CD4 + T细胞淋巴细胞减少症的治疗方法

    公开(公告)号：US5728560A

    公开(公告)日：1998-03-17

    申请号：US663685

    申请日：1996-06-14

    申请人： Robert G. L. Shorr ,  Mike A. Clark ,  David H. Goddard

    发明人： Robert G. L. Shorr ,  Mike A. Clark ,  David H. Goddard

    IPC分类号： A61K38/46 ,  A61K47/48 ,  A61K38/43 ,  C12N9/00 ,  C12N9/78

    CPC分类号： A61K47/48215 ,  A61K31/7072 ,  A61K38/50 ,  C12Y305/04004

    摘要： The present invention is directed to methods of treating CD4+ T cell lymphopenia in HIV-infected patients. The methods include administering an effective mount of adenosine deaminase or related enzymatic material to a patient in need thereof. In preferred aspects of the invention, the method is employed in conjunction with HIV-infected patients having CD4+ T cell levels of less than about 200/.mu.l. Effective amounts of the enzyme range from about 5 to about 50 IU/kg/week. In one particularly preferred aspect of the invention, the adenosine deaminase is conjugated to one or more strands of polyethylene glycol to prolonged activity in vivo.

    摘要翻译： 本发明涉及在HIV感染患者中治疗CD4 + T细胞淋巴细胞减少症的方法。 所述方法包括向有需要的患者施用有效载体的腺苷脱氨酶或相关酶材料。 在本发明的优选方面，该方法与CD4 + T细胞水平小于约200 /μl的HIV感染患者结合使用。 酶的有效量范围为约5至约50IU / kg /周。 在本发明的一个特别优选的方面，腺苷脱氨酶与一个或多个聚乙二醇链共轭以延长体内的活性。